FECES - Fecal transplantation to Eradicate Colonizing Emergent Superbugs

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516393-29-00

Acronym

APHP180587

Enrollment

299

Registered

2024-12-03

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients colonized with MDR-GNB

Brief summary

Proportion of subjects not carrying MDR-GNB (neither carbapenem-resistant Enterobacteriaceae [CRE] nor extended spectrum β-lactamase producing Enterobacteriaceae [ESBL-E]) at 30 ± 10 days after randomization, as determined by culture methods

Interventions

DRUGPlacebo double encapsulated oral transplant of fecal microbiota

DRUGDouble encapsulated oral transplant of fecal microbiota

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Proportion of subjects not carrying MDR-GNB (neither carbapenem-resistant Enterobacteriaceae [CRE] nor extended spectrum β-lactamase producing Enterobacteriaceae [ESBL-E]) at 30 ± 10 days after randomization, as determined by culture methods	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026